Anlotinib combined with benmelstobart as a chemo-free first-line treatment in advanced esophageal squamous cell carcinoma: an exploratory multicenter, single-arm phase II clinical trial.
Saved in:
| Title: | Anlotinib combined with benmelstobart as a chemo-free first-line treatment in advanced esophageal squamous cell carcinoma: an exploratory multicenter, single-arm phase II clinical trial. |
|---|---|
| Authors: | Meng, Xiangrui1 (AUTHOR), Yang, Xiuli2 (AUTHOR), Hong, Yonggui3 (AUTHOR), Wang, Wenkang4 (AUTHOR), Zhang, Zhiye5 (AUTHOR), Xia, Jin3 (AUTHOR), Chen, Yunfang6 (AUTHOR), Zhou, Yue7 (AUTHOR), Lu, Taiying1 (AUTHOR), Song, Min1 (AUTHOR), Shan, Zhengzheng1 (AUTHOR), Wu, Tao3 (AUTHOR), Wu, Weilong3 (AUTHOR), Shen, Ling2 (AUTHOR), Guan, Lulu1 (AUTHOR), Ma, Mingying5 (AUTHOR), Wang, Lisen6 (AUTHOR), Luo, Xi1 (AUTHOR), Xin, Dao1 (AUTHOR), Ma, Yihui8 (AUTHOR) |
| Source: | Molecular Cancer. 6/11/2025, Vol. 24 Issue 1, p1-13. 13p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
